The question, “What is your capacity?” is one that every CDMO faces, yet the most honest answer remains, “It depends.”
Capacity in pharmaceutical contract manufacturing has become a challenge owing to rising demand for complex modalities such as sterile injectables, biologics, and advanced therapies. This is combined with limited skilled labour, lengthy facility and equipment lead times, and persistent supply chain vulnerabilities. These challenges have made capacity a moving target rather than a fixed number.
This session will examine how pharma companies and their CDMO partners can better navigate current pressures by rethinking how capacity is planned, managed, and communicated.
Discussion points will include:
- Leveraging technology and data: Enhancing visibility and applying predictive analytics to anticipate bottlenecks and optimise resource allocation.
- Adopting flexible manufacturing models: Building agility through modular facilities, multi-product lines, and scalable partnerships that can flex with market demand.
- Strengthening oversight and governance: Developing robust internal frameworks that ensure accountability, quality, and efficiency across outsourced networks.